NCT05826028已完成不适用
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 368
- 试验地点
- 1
- 主要终点
- Average time for siponimod onboarding
研究概览
简要总结
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in Australia to Mayzent (siponimod) treatment.
Initiating siponimod involves pre-screen tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. The MSGo platform was developed to support onboarding. It is an integrated digital platform that functions as a patient support service.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Average time for siponimod onboarding
时间窗: Up to 168 days
次要结局
- Time to siponimod onboarding in pre-specified sub-groups(Up to 168 days)
- Percentage of patients who adhered to the titration protocol(Up to 168 days)
- Time on maintenance therapy(Up to 168 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma PatientsMetastatic MelanomaNCT06369428Novartis1,795
Unknown
不适用
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyAcute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Non Hodgkin Lymphoma (NHL)Hodgkin Lymphoma, AdultNCT03260101Cellect Biotechnology12
已完成
不适用
HLH Patients - a Retrospective StudyHemophagocytic LymphohistiocytosesNCT05531721Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna39
已完成
不适用
A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.Locally Advanced or Metastatic EGFR Mutated NSCLC.NCT01955681AstraZeneca200
已完成
不适用
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult PatientsHypercholesterolemiaNCT06595069Novartis600